Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

2728 results

Sort By:

NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer

Study ID: NCT07224152
Start Date: 2026-04-30
End Date: 2030-08-30
Study Type

Interventional

Study Phase

Phase2

No. of Participants

40

Intervention / Treatment

NBTXR3

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Vitamin D Supplementation in Critically Ill Children With Respiratory Diseases

Study ID: NCT06547749
Start Date: 2025-12
End Date: 2027-12
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

40

Intervention / Treatment
Sponsor

Assiut University

Source: clinicaltrials.gov

Share:
Add to list

Food DNA Digestion

Study ID: NCT06687226
Start Date: 2026-07-01
End Date: 2027-07-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

20

Intervention / Treatment

Reconstitutable food powder

Sponsor

Duke University

Source: clinicaltrials.gov

Share:
Add to list

Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)

Study ID: NCT07153497
Start Date: 2026-02-26
End Date: 2030-04-26
Study Type

Interventional

Study Phase

Phase2

No. of Participants

132

Intervention / Treatment

Biospecimen Collection

Bone Marrow Aspiration

Bone Marrow Biopsy

Decitabine and Cedazuridine

Olutasidenib

Venetoclax

Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list

Virtual Caregiver Coach for You (ViCCY)

Study ID: NCT07220798
Start Date: 2026-06-15
End Date: 2029-09-15
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

314

Intervention / Treatment

ViCCY

Sponsor

Visiting Nurse Service of New York

Source: clinicaltrials.gov

Share:
Add to list

TranExamic Atomized for Pediatric Post-Operative Tonsillectomy Hemorrhage

Study ID: NCT06580509
Start Date: 2025-12
End Date: 2028-09-30
Study Type

Interventional

Study Phase

Early_phase1

No. of Participants

12

Intervention / Treatment

Tranexamic Acid Injectable Product

Normal Saline

Sponsor

The University of Texas Health Science Center at San Antonio

Source: clinicaltrials.gov

Share:
Add to list

Project for Reproductive Equity Through Volunteers and Entrepreneurship, Networks and Technology

Study ID: NCT03995043
Start Date: 2026-12
End Date: 2028-06-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

198

Intervention / Treatment

Education

Personal Support

Access to contraception

Sponsor

Dr. Karen Yeates

Source: clinicaltrials.gov

Share:
Add to list

Multiple Micronutrient Supplementation (MMS) vs IFA Acceptability Crossover Trial

Study ID: NCT06069856
Start Date: 2026-01
End Date: 2026-07
Study Type

Interventional

Study Phase

Phase3

No. of Participants

130

Intervention / Treatment

Iron Folic Acid Tablets with 60 mg of iron

Multiple Micronutrient Supplements with 60 mg of elemental iron

Sponsor

George Washington University

Source: clinicaltrials.gov

Share:
Add to list

Cardiac Simulator for Surgical Planning

Study ID: NCT06373705
Start Date: 2026-04
End Date: 2029-04
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

275

Intervention / Treatment

Cardiac simulator

Sponsor

Stanford University

Source: clinicaltrials.gov

Share:
Add to list

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

Study ID: NCT06948786
Start Date: 2025-11-14
End Date: 2031-07-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

22

Intervention / Treatment

Pirtobrutinib

Mosunetuzumab

Biospecimen Collection

Biopsy Procedure

Computed Tomography

Positron Emission Tomography

Bone Marrow Aspiration

Bone Marrow Biopsy

Administration Questionnaire

Sponsor

University of Washington

Source: clinicaltrials.gov

Share:
Add to list